State Of The Union For Breast Cancer:
Edited in Houston, Texas by Trenette Allen
Dallas ( AP ) ---- A women getting married in 2015 under the age of 40 has an 85% chance of surviving due to a breast cancer diagnosis. Genomics and Informatics is on the goal line. Barron’s Medical Journal says a cure may happen before the end of President Obama's second term.
Informatics is the science of information. As an academic field, it involves the practice of information processing, and the engineering of information systems. 
It studies the structure, algorithms, behavior, and interactions of natural and artificial systems which store, process, access, and communicate information.
We spoke with the Chief Information Officer of the informatics technology company Gen-Tek Inc. and what we found was a demand in the clinical trial setting
and research center across the United States is at an all- time high. In fact, an Informatics engineer has a 97% chance of having a job offer before they graduate.
Breast cancer research two major developments: targeted treatments (small molecule inhibitors and monoclonal antibodies) and massive parallel sequencing of tumor genomes,
also known as next-generation sequencing (NGS). By using these platforms, a great deal of information can be obtained in a very short time.
Cancer cells are dependent on oncogenic expression to maintain malignancy, and these can be used as predictive biomarkers. Examples include the following: oncogene addiction as in HER2 amplification in breast cancer, the KIT mutation in gastrointestinal stromal tumors, epidermal growth factor receptor mutations and/or amplification in nonsmall cell lung cancer, and the BRAF V600E mutation in melanoma. Data obtained from sequencing tumors from patients with breast cancer has revealed a high level of intertumor and intratumor heterogeneity, with very few highly recurrent mutations. It has also become apparent that not every tumor has an identifiable driver mutation, and not all drivers of metastatic disease or resistance have been identified. “It is only by harnessing the knowledge from intra- and intertumor heterogeneity that we will be able to realize the application of precision medicine.
The truth of the matter is, we treat cancer today, we guess. We take what we call the average results, put it in, and see if it works. If it doesn't work, oops, we'll try another drug. If it does work, we stop the drug. When you look back 10 years from now, it's almost barbaric.
Dr. Soon-Shiong 62-year-old native of South Africa can afford to be outspoken because of his immense wealth. He doesn't need to rely on the government or Big Pharma for funding. Soon-Shiong is certain that what he terms "the Dark Age of cancer treatment" is nearly over, and "the Enlightened Age" is about to begin.
The treatment doesn't need to be painful. Metastasis doesn't need to be a death sentence. Cancer could be a chronic disease...and treated towards the cure.
While the oncology world may cringe when he boasts, as he's prone to do, patients see him differently. He believes chemotherapy works best when administered in frequent, low doses and that in some cancers the traditional method of blasting a tumor with heavy doses of chemotherapy may actually be counterproductive - because it could induce cancer cells to escape the hostile environment, enter the bloodstream and find a new home. Soon-Shiong has teamed with Blackberry to produce a device that will identify for patients and doctors what they need to make more informed decisions.
Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). We then ask Rose is her company doing any work with Genomics for breast cancer and if so explain the process. Genomics is the Gaussian processes in action, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Sam Houston to make treatment recommendations for certain node-positive breast cancer patients, and the test report
also provides quantitative scores for select individual genes. Sam Houston has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Sam Houston for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions.
Breast cancer researchers and scientists are ahead of the curve with several new technologies based on nanoparticles and semi conductors namely genomics and treatments. The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.
The result is that the ability to determine targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data. The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3,000.00. The lower cost, along with increasing speed, has led to a huge increase in how much breast cancer sequencing data is being produced.
Numerous investigations have shown that both tissue and cell distribution profiles of anti-cancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The invivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism 
involved in tumor regression. Nanoparticles are also a benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells.
Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid Sam Houston researchers say that nanotechnology will allow them to run many diagnostic tests simultaneously.
Nanoparticles nanoshells is use to antibodies that
recognize cancer cells. Sam Houston scientists envision letting these nanoshells seek out their cancerous targets, then apply near-infrared light. The heat generated by the light-absorbing nanoshells can successfully kill breast cancer tumor cells while leaving neighboring cells intact.
No comments:
Post a Comment